Patents by Inventor Clive Allan Prestidge
Clive Allan Prestidge has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 10463626Abstract: A dry composition, comprising three-dimensional porous microparticles, wherein the microparticles comprise: (i) an active substance (eg a poorly water soluble drug), (ii) polymeric nanoparticles such as those composed of a biocompatible and/or biodegradable polymer (eg a PLGA polymer) (iii) lipid droplets (eg droplets of a medium chain triglyceride (MCT)), (iv) a nanoparticle stabilizing agent such as PVA or DMAB, and optionally, (v) a cryoprotectant (eg mannitol); wherein said active substance is carried by said nanoparticles and/or lipid droplets. The composition of the present invention may be formulated into, for example, a medicament for the treatment and/or prevention of various diseases or disorders (eg human or veterinary therapeutics). The average diameter of the individual microparticles of the composition, may be in the order of 2.5-3.5 ?m which are particularly suitable for administration to the lung.Type: GrantFiled: March 11, 2016Date of Patent: November 5, 2019Assignee: University of South AustraliaInventors: Clive Allan Prestidge, Paul Matthew Joyce
-
Publication number: 20180092854Abstract: A dry composition, comprising three-dimensional porous microparticles, wherein the microparticles comprise: (i) an active substance (eg a poorly water soluble drug), (ii) polymeric nanoparticles such as those composed of a biocompatible and/or biodegradable polymer (eg a PLGA polymer) (iii) lipid droplets (eg droplets of a medium chain triglyceride (MCT)), (iv) a nano-particle stabilising agent such as PVA or DMAB, and optionally, (v) a cryoprotectant (eg mannitol); wherein said active substance is carried by said nanoparticles and/or lipid droplets. The composition of the present invention may be formulated into, for example, a medicament for the treatment and/or prevention of various diseases or disorders (eg human or veterinary therapeutics). The average diameter of the individual microparticles of the composition, may be in the order of 2.5-3.5 ?m which are particularly suitable for administration to the lung.Type: ApplicationFiled: March 11, 2016Publication date: April 5, 2018Inventors: Clive Allan PRESTIDGE, Paul Matthew JOYCE
-
Publication number: 20170165199Abstract: A method of producing a dried formulation for an active substance such as a drug compound is described. The method involves dispersing a discontinuous phase (e.g. an oil-based or lipidic medium) comprising the active substance into a continuous phase (e.g. water) so as to form a two-phase liquid system comprising droplets of said discontinuous phase, allowing nanoparticles to congregate at the phase interface at the surface of the droplets such that at least one layer of nanoparticles coat the droplets and thereby provide sufficient structural integrity to the droplets to enable the subsequent removal of the continuous phase, and thereafter removing the continuous phase from the nanoparticle-coated droplets to produce a dried formulation.Type: ApplicationFiled: September 27, 2016Publication date: June 15, 2017Applicant: University of South AustraliaInventors: Clive Allan Prestidge, Spomenka SIMOVIC
-
Patent number: 8778400Abstract: A formulation for the delivery of an anti-inflammatory agent to a subject is described. In one particular application of the invention, the formulation comprises oil-based or aqueous droplets comprising indomethacin (1-(4-chlorobenzoyl)-5-methoxy-2-methyl-1-H-indole-3-acetic acid) or celecoxib (4-[5-(4-methylphenyl)-3-(trifluoromethyl) pyrazol-1-yl]benzenesulfonamide) stabilized by nanoparticles, particularly silica nanoparticles.Type: GrantFiled: April 20, 2009Date of Patent: July 15, 2014Assignee: University of South AustraliaInventors: Clive Allan Prestidge, Spomenka Simovic
-
Patent number: 8303992Abstract: A method of producing a dried formulation for an active substance such as a drug compound is described. The method involves dispersing a discontinuous phase (e.g. an oil-based or lipidic medium) comprising the active substance into a continuous phase (e.g. water) so as to form a two-phase liquid system comprising droplets of said discontinuous phase, allowing nanoparticles to congregate at the phase interface at the surface of the droplets such that at least one layer of nanoparticles coat the droplets and thereby provide sufficient structural integrity to the droplets to enable the subsequent removal of the continuous phase, and thereafter removing the continuous phase from the nanoparticle-coated droplets to produce a dried formulation.Type: GrantFiled: October 12, 2010Date of Patent: November 6, 2012Assignee: University of South AustraliaInventors: Clive Allan Prestidge, Spomenka Simovic
-
Publication number: 20110229559Abstract: Methods of producing a controlled release formulation for an active substance are disclosed, wherein the methods involve dispersing a discontinuous phase comprising an active substance into a continuous phase so as to form a two-phase liquid system comprising droplets of said discontinuous phase, and allowing nanoparticles provided to the two-phase liquid system to congregate at the phase interface to thereby coat the surface of the droplets in at least one layer of said nanoparticles. The methods utilise a concentration of a suitable electrolyte which enhances the nanoparticle congregation such that the coating of nanoparticles on the surface of the droplets presents a semi-permeable barrier to the active substance, or otherwise utilise a amount of the active substance that is greater than the solubility limit of that active substance in the discontinous phase. Formulations comprising vitamin A (retinol) as the active substance for dermal delivery are specifically exemplified.Type: ApplicationFiled: March 28, 2011Publication date: September 22, 2011Applicant: University of South AustraliaInventors: Clive Allan Prestidge, Spomenka Simovic, Nasrin Ghouchi Eskandar
-
Publication number: 20110027454Abstract: A method of producing a dried formulation for an active substance such as a drug compound is described. The method involves dispersing a discontinuous phase (e.g. an oil-based or lipidic medium) comprising the active substance into a continuous phase (e.g. water) so as to form a two-phase liquid system comprising droplets of said discontinuous phase, allowing nanoparticles to congregate at the phase interface at the surface of the droplets such that at least one layer of nanoparticles coat the droplets and thereby provide sufficient structural integrity to the droplets to enable the subsequent removal of the continuous phase, and thereafter removing the continuous phase from the nanoparticle-coated droplets to produce a dried formulation.Type: ApplicationFiled: October 12, 2010Publication date: February 3, 2011Applicant: University of South AustraliaInventors: Clive Allan Prestidge, Spomenka Simovic
-
Publication number: 20100136124Abstract: A method and formulation for the delivery of an active substance to the skin (epidermis, including the stratum corneum and viable epidermis, and dermis) of a subject. The formulation comprises oil-based or aqueous droplets comprising the active substance within a coating of nanoparticles, particularly silica nanoparticles. The active substance may be suitable for the treatment of a disease or condition which is localised, or at least partially localised, to the skin (eg skin cancer, psoriasis, eczema, infections including bacterial and fungal infections, acne, dermatitis, inflammation, and rheumatoid arthritis).Type: ApplicationFiled: April 21, 2008Publication date: June 3, 2010Applicant: UNIVERSITY OF SOUTH AUSTRALIAInventors: Clive Allan Prestidge, Spomenka Simovic, Nasrin Ghouchi Eskandar
-
Publication number: 20090263486Abstract: A formulation for the delivery of an anti-inflammatory agent to a subject is described. In one particular application of the invention, the formulation comprises oil-based or aqueous droplets comprising indomethacin (1-(4-chlorobenzoyl)-5-methoxy-2-methyl-1-H-indole-3-acetic acid) or celecoxib (4-[5-(4-methylphenyl)-3-(trifluoromethyl) pyrazol-1-yl] benzenesulfonamide) stabilised by nanoparticles, particularly silica nanoparticles.Type: ApplicationFiled: April 20, 2009Publication date: October 22, 2009Applicant: University of South AustraliaInventors: Clive Allan PRESTIDGE, Spomenka Simovic
-
Publication number: 20090181076Abstract: Methods of producing a controlled release formulation for an active substance are disclosed, wherein the methods involve dispersing a discontinuous phase comprising an active substance into a continuous phase so as to form a two-phase liquid system comprising droplets of said discontinuous phase, and allowing nanoparticles provided to the two-phase liquid system to congregate at the phase interface to thereby coat the surface of the droplets in at least one layer of said nanoparticles. The methods utilise a concentration of a suitable electrolyte which enhances the nanoparticle congregation such that the coating of nanoparticles on the surface of the droplets presents a semi-permeable barrier to the active substance, or otherwise utilise a amount of the active substance that is greater than the solubility limit of that active substance in the discontinous phase. Formulations comprising vitamin A (retinol) as the active substance for dermal delivery are specifically exemplified.Type: ApplicationFiled: May 4, 2007Publication date: July 16, 2009Applicant: University of South AustraliaInventors: Clive Allan Prestidge, Spomenka Simovic, Nasrin Ghouchi Eskandar
-
Publication number: 20080193513Abstract: A method of producing a dried formulation for an active substance such as a drug compound is described. The method involves dispersing a discontinuous phase (e.g. an oil-based or lipidic medium) comprising the active substance into a continuous phase (e.g. water) so as to form a two-phase liquid system comprising droplets of said discontinuous phase, allowing nanoparticles to congregate at the phase interface at the surface of the droplets such that at least one layer of nanoparticles coat the droplets and thereby provide sufficient structural integrity to the droplets to enable the subsequent removal of the continuous phase, and thereafter removing the continuous phase from the nanoparticle-coated droplets to produce a dried formulation.Type: ApplicationFiled: June 7, 2006Publication date: August 14, 2008Applicant: University of South AustraliaInventors: Clive Allan Prestidge, Spomenka Simovic